7 completed, 1 terminated. 6 Phase 2, 2 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 6 | Completed 5, Terminated 1 |
| Phase 3 | 2 | Completed 2 |
Follow CK-2017357: new trials by email Literature Review of CK-2017357 trials Research Report on CK-2017357
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study for Patients Who Completed VITALITY-ALS (CY 4031) tirasemtiv - Amyotrophic Lateral Sclerosis (ALS) | Phase 3 | Completed | Cytokinetics | 280 | 2016-10-17 | 2021-06-15 |
| Ventilatory Investigation of Tirasemtiv and Assessment of Longitudinal Indices After Treatment for a Year Tirasemtiv, Placebo tablets - Amyotrophic Lateral Sclerosis | Phase 3 | Completed | Cytokinetics | 744 | 2015-09-03 | 2020-09-09 |
| Study of Safety, Tolerability & Efficacy of CK-2017357 in Amyotrophic Lateral Sclerosis (ALS) CK-2017357, Placebo tablets, Riluzole - Amyotrophic Lateral Sclerosis | Phase 2 | Completed | Cytokinetics | 711 | 2012-10-01 | 2020-03-31 |
| Dose Titration Study to Test Safety and Effects of CK-2017357 in Patients With Amyotrophic Lateral Sclerosis (ALS) CK-2017357, Placebo, Riluzole 50 MG - Amyotrophic Lateral Sclerosis | Phase 2 | Completed | Cytokinetics | 27 | 2011-11-01 | 2019-05-03 |
| A Study to Evaluate the Effects of Multiple Doses of CK-2017357 in Patients With Amyotrophic Lateral Sclerosis (ALS) Placebo (Part A), CK-2017357 (Part A), Riluzole 50 MG (Part B) - Amyotrophic Lateral Sclerosis | Phase 2 | Completed | Cytokinetics | 49 | 2011-06-01 | 2019-05-07 |
| Pharmacodynamic Study of CK-2017357 in Patients With Generalized Myasthenia Gravis Placebo, 250 mg CK-2017357, 500 mg CK-2017357 - Myasthenia Gravis | Phase 2 | Terminated | Cytokinetics | 32 | 2010-12-01 | 2019-09-24 |
| A Study of CK-2017357 in Patients With Peripheral Artery Disease and Symptomatic Claudication Placebo, 375 mg CK-2017357, 500 mg CK-2017357 - Intermittent Claudication, Peripheral Artery Disease | Phase 2 | Completed | Cytokinetics | 61 | 2010-05-01 | 2019-05-14 |
| A Study of CK-2017357 in Patients With Amyotrophic Lateral Sclerosis (ALS) Placebo, 250 mg CK-2017357, 500 mg CK-2017357 - Amyotrophic Lateral Sclerosis | Phase 2 | Completed | Cytokinetics | 67 | 2010-03-01 | 2019-05-10 |
Amyotrophic Lateral Sclerosis (6) · Intermittent Claudication (1) · Myasthenia Gravis (1) · Peripheral Arterial Disease (1)
Cytokinetics (8)
United States (8) · Canada (3) · France (3) · Germany (3) · Ireland (3) · Netherlands (3) · Spain (3) · United Kingdom (3) · Belgium (2) · Italy (2) · Portugal (2)
Jeremy Shefner, MD, PhD (3) · Alan Hirsch, MD (1) · Andrew Wolff, MD, FACC (1) · Jeremy M Shefner, MD, PhD (1) · Jinsy Andrews, MD (1) · William Hiatt, MD (1)
PMID 22591195, PMID 23952636, PMID 24872402, PMID 29402141, PMID 39513379
1RC3NS070670-01 (1), 2014 (1), 2016 (1)